255 related articles for article (PubMed ID: 10479130)
1. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.
Notermans DW; Pakker NG; Hamann D; Foudraine NA; Kauffmann RH; Meenhorst PL; Goudsmit J; Roos MT; Schellekens PT; Miedema F; Danner SA
J Infect Dis; 1999 Oct; 180(4):1050-6. PubMed ID: 10479130
[TBL] [Abstract][Full Text] [Related]
2. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
Fransen S; Copeland KF; Smieja M; Smaill F; Rosenthal KL
J Infect Dis; 2000 Feb; 181(2):505-12. PubMed ID: 10669333
[TBL] [Abstract][Full Text] [Related]
3. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
4. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
[TBL] [Abstract][Full Text] [Related]
5. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
Connick E; Lederman MM; Kotzin BL; Spritzler J; Kuritzkes DR; St Clair M; Sevin AD; Fox L; Chiozzi MH; Leonard JM; Rousseau F; D'Arc Roe J; Martinez A; Kessler H; Landay A
J Infect Dis; 2000 Jan; 181(1):358-63. PubMed ID: 10608789
[TBL] [Abstract][Full Text] [Related]
6. Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS.
Chougnet C; Jankelevich S; Fowke K; Liewehr D; Steinberg SM; Mueller BU; Pizzo PA; Yarchoan R; Shearer GM
J Infect Dis; 2001 Jul; 184(2):201-5. PubMed ID: 11424019
[TBL] [Abstract][Full Text] [Related]
7. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
[TBL] [Abstract][Full Text] [Related]
8. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
10. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
Markowitz M; Vesanen M; Tenner-Racz K; Cao Y; Binley JM; Talal A; Hurley A; Jin X; Chaudhry MR; Yaman M; Frankel S; Heath-Chiozzi M; Leonard JM; Moore JP; Racz P; Nixon DF; Ho DD
J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
[TBL] [Abstract][Full Text] [Related]
11. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
Rinaldo CR; Liebmann JM; Huang XL; Fan Z; Al-Shboul Q; McMahon DK; Day RD; Riddler SA; Mellors JW
J Infect Dis; 1999 Feb; 179(2):329-36. PubMed ID: 9878015
[TBL] [Abstract][Full Text] [Related]
12. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.
Angel JB; Parato KG; Kumar A; Kravcik S; Badley AD; Fex C; Ashby D; Sun E; Cameron DW
J Infect Dis; 2001 Feb; 183(4):546-54. PubMed ID: 11170979
[TBL] [Abstract][Full Text] [Related]
13. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Goodgame JC; Pottage JC; Jablonowski H; Hardy WD; Stein A; Fischl M; Morrow P; Feinberg J; Brothers CH; Vafidis I; Nacci P; Yeo J; Pedneault L
Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
[TBL] [Abstract][Full Text] [Related]
14. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
15. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
16. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Gray CM; Schapiro JM; Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
[TBL] [Abstract][Full Text] [Related]
20. Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.
Seth A; Markee J; Hoering A; Sevin A; Sabath DE; Schmitz JE; Kuroda MJ; Lifton MA; Hirsch MS; Collier AC; Letvin NL; McElrath MJ
J Infect Dis; 2001 Mar; 183(5):722-9. PubMed ID: 11181148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
